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Abstract
Objective To determine the expected duration of symptoms of common
respiratory tract infections in children in primary and emergency care.
Design Systematic review of existing literature to determine durations
of symptoms of earache, sore throat, cough (including acute cough,
bronchiolitis, and croup), and common cold in children.
Data sources PubMed, DARE, and CINAHL (all to July 2012).
Eligibility criteria for selecting studies Randomised controlled trials
or observational studies of children with acute respiratory tract infections
in primary care or emergency settings in high income countries who
received either a control treatment or a placebo or over-the-counter
treatment. Study quality was assessed with the Cochrane risk of bias
framework for randomised controlled trials, and the critical appraisal
skills programme framework for observational studies.
Main outcome measures Individual study data and, when possible,
pooled daily mean proportions and 95% confidence intervals for symptom
duration. Symptom duration (in days) at which each symptom had
resolved in 50% and 90% of children.
Results Of 22 182 identified references, 23 trials and 25 observational
studies met inclusion criteria. Study populations varied in age and
duration of symptoms before study onset. In 90% of children, earache
was resolved by seven to eight days, sore throat between two and seven
days, croup by two days, bronchiolitis by 21 days, acute cough by 25
days, common cold by 15 days, and non-specific respiratory tract
infections symptoms by 16 days.
Conclusions The durations of earache and common colds are
considerably longer than current guidance given to parents in the United
Kingdom and the United States; for other symptoms such as sore throat,
acute cough, bronchiolitis, and croup the current guidance is consistent
with our findings. Updating current guidelines with new evidence will
help support parents and clinicians in evidence based decision making
for children with respiratory tract infections.
Introduction
Respiratory tract infections are particularly common in children;
most are self limiting and the risk of complications is small.
Recommended management therefore typically involves self
care and treatment of symptoms. Nevertheless, such infections
still account for over a third of paediatric consultations to
primary care in the United Kingdom and the United States,1 2
and antibiotics are commonly prescribed in many countries
despite limited evidence of effectiveness.
One of the most common questions that parents ask when
consulting healthcare services is “how long will my child’s
symptoms last?” Accurate information about the expected course
of respiratory tract infections in children is essential for both
clinicians and parents, as it sets expectations and lets them know
when the illness is deviating from the expected.3 4 This directly
informs parents’ decisions to seek medical attention, whether
to re-consult, and when to use delayed prescriptions of
antibiotics, as well as clinicians’ decisions on when to prescribe
antibiotics or consider other treatments.3 5-7
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Commonly used estimates of the expected time course of
symptoms of common respiratory tract infections are highly
variable and not always evidence based. For example, the 2008
National Institute for Health and Care Excellence guidelines
for treatment of respiratory tract infections include estimates of
average duration of the illness (before and after seeing a doctor)
of four days for acute otitis media, one week for acute sore
throat, one and a half weeks for the common cold, and three
weeks for acute cough or bronchitis.8 By contrast, information
for patients from the US Centers for Disease Control and
Prevention describe sore throat as lasting one to two weeks,
common cold lasting up to two weeks, and cough duration
ranging from two to eight weeks.9 The durations quoted in these
sources reflect findings based on expert opinion or from
individual studies rather than from data synthesis of multiple
studies and are not child specific. We therefore conducted a
systematic review of the literature on symptom durations of the
most common respiratory tract infections (earache, sore throat,
cough, and common cold) in children presenting to primary
care.
Methods
Selection
Studies were eligible for inclusion if they recruited otherwise
healthy children (birth to 18 years) with acute respiratory
infections presenting to primary care or emergency department
settings; were conducted in high income countries, as defined
by the Organisation for Economic Co-operation and
Development10; provided data on time to resolution of symptoms
or complete duration of symptoms; involved placebo or no
treatment arms of controlled non-surgical treatment trials or
prospective observational studies; and reported in English.
Although respiratory tract infections can include a cluster of
various symptoms, certain symptoms (such as cough)
predominate in clinical experience and in published trials,
depending on a child’s illness, ability to describe his or her
symptoms, and/or parental recognition and interpretation of
symptoms.11 Given this, we chose to not only include studies
of children presenting with clustered symptoms (such as
common cold or undifferentiated respiratory tract infections)
but also those of individual symptoms (such as sore throat). We
included studies of children presenting with primary complaints
of earache (acute otitis media), sore throat (or pharyngitis or
tonsillitis), cough (or acute bronchitis, bronchiolitis, or croup),
and common cold (or upper respiratory tract infection).
We excluded studies of children with chronic, recurrent, or
complicated infections; experimentally induced infection; or
medical conditions associated with a high risk of serious
infections (such as cystic fibrosis, immunodeficiency). We also
excluded studies conducted in inpatient settings or in low or
middle income countries as defined by the Organisation for
Economic Co-operation and Development, where the risk of
complications from infection might be higher. Studies that
reported data on both children and adults were included only if
data were presented separately by age. We excluded trials
comparing two active treatments, those of prophylactic or
adjuvant treatments, and retrospective studies; studies with
follow-up of 24 hours or less; and studies that presented
symptom duration only before consultation, assessed only
incidence or prevalence, or presented duration of symptoms by
symptom score or individual pathogen.
Search
We identified relevant intervention trials and observational
studies using two search strategies (appendix 1). Firstly, we
conducted searches in PubMed, DARE, and CINAHL (all
databases searched through July 2012) to identify randomised
controlled trials and systematic reviews of trials for each of the
four symptoms of respiratory tract infection (sore throat, cough,
common cold, and earache). Search terms included clinical
syndromes and symptoms, study design, and paediatric
population with both MeSH and free text terms. We also hand
searched the Cochrane Acute Respiratory Infections and Ear,
Nose and Throat Groups for systematic reviews of randomised
controlled trials. Secondly, we searched PubMed (1966-July
2012) for observational studies of children with acute sore throat,
cough, common cold, or earache using terms for clinical
syndromes and symptoms, child, and limited by publication
type (that is, excluding clinical trials and systematic reviews of
clinical trials). We reviewed reference lists of selected studies
identified using both of these strategies and searched related
citations to identify additional references. One author (TAV)
screened titles and abstracts using the inclusion and exclusion
criteria. Two authors (TAV and MT) reviewed the full text of
all potentially relevant studies to determine final inclusion.
Data extraction
Two authors (TAV andMT) independently extracted data using
a predetermined template. Authors were not blinded to any
aspect of the studies during extraction, and disagreements were
resolved by consensus (TAV, MT, and DIB/CH). We extracted
data on country and setting of study; population; length of
follow-up; description of presenting symptom(s) and/or
diagnostic criteria; description of intervention and control;
definition of usual care in placebo arms of trials; specified
outcome(s); outcome assessor (parent, child, clinician, or
investigator); method of outcome assessment; and data on
adverse events (complications, re-consultations, admission to
hospital).
The outcomes of interest were time to resolution of symptoms
or duration of symptoms. These included time taken for
prespecified proportions (such as 50%) of children’s symptoms
to have resolved, the study population, proportion of children
with unresolved symptoms at follow-up, or mean or median
duration of symptoms. For studies of common cold or
undefined/non-specific respiratory tract infections, we extracted
data on symptom duration for the cluster of symptoms
comprising a cold as defined in each study (reported in appendix
2). We extracted data from studies that reported proportions of
children with symptoms at time points, provided continuous
data from which proportions could be inferred, or presented
mean (and 95% confidence interval) durations of symptoms.
When available we also extracted data on symptom duration
before consultation. We extracted data only from the
non-intervention (that is, placebo) arms of included randomised
controlled trials. Data from line graphs were extracted with
DigitizeIt software (DigitizeIt 2010, version 4.0.2, Carrascal).
Quality assessment
Two authors (TAV and MT) independently assessed quality of
included studies using the Cochrane risk of bias framework for
randomised controlled trials12 and the critical appraisal skills
programme13 framework for observational studies.
Disagreements were resolved by consensus (TAV, MT, and
DIB/CH). Judgment regarding risk of bias (“high,” “low,” or
“unclear risk of bias”) was made for each criterion.
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Data synthesis
We report data on duration of symptoms for each symptom
category from each study.When possible (that is, at time points
included in two or more studies) we calculated the pooled daily
mean proportions and 95% confidence intervals for symptom
duration and presented summary data visually. Given the
heterogeneity in study populations and inconsistent methods of
assessment, we have also presented the individual study data
in addition to pooled means to display the variation in symptom
durations. We identified the mean time point (as number of
whole days) at which the symptom was resolved in 50% and in
90% of children with that particular symptom. Though we had
planned to carry out subgroup analyses based on age and
symptom duration before enrolment, we were unable to do so
because of insufficient data.
Results
The search for randomised controlled trials identified 10 829
papers; after review of titles and/or abstracts we excluded 10
637 (fig 1⇓). Based on full text review of 192 papers, we
excluded a further 169 and included 23 trials in the analysis.
The search for observational studies identified 11 353 papers;
after review of titles and/or abstracts we excluded 11 226 (fig
2⇓), and after review of the full text of 127 we excluded 102,
leaving 25 observational studies in the analysis. We present
results separately by type of symptom of respiratory tract
infection.
Earache
We included data from seven trials with 958 children14-20 and
three observational studies with 451 children21-23 (tables 1⇓ and
2⇓). Included trials and studies came from the UK,14 23 USA,16
Netherlands,15 Sweden,19 Denmark,18 Finland,20 Canada,17
Poland,22 and Israel21 (appendix 2).
Earache was generally present less than four days before study
entry, and follow-up ranged from eight days to four months in
randomised controlled trials, and 21 days to a year in
observational studies. In most studies, parents assessed symptom
duration14-17 19-23 using daily symptom diaries, telephone
interviews, or in person questionnaires. Most studies had low
risk of bias, though assessment of bias was difficult because of
unclear methods in two studies18 23 (appendix 3). Risk of bias
was highest in the study by Neumark and colleagues,19 which
used an open trial design with no blinding among parents or
clinicians.
Among the five studies that reported mean duration, symptoms
of earache lasted from half a day to nine days14 15 19 21 22 (table
1⇓). Based on the pooled results from 10 studies, 50% of
children’s symptoms had resolved at day three and 90% by days
seven to eight (fig 3⇓). Damoiseaux and colleagues15 and
Greenberg and colleagues21 reported fever (as well as earache)
lasting three days (median) and 2.9 days (mean, SD 2.6),
respectively.
Sore throat
We included six trials on 241 children24-29 and one observational
study of 103 infants.22 Most trials took place in North
America,24 26 27 with the remainder from the UK,25 Italy,28 and
the Netherlands.29 The single observational study was conducted
in Poland.22
Characteristics of patients varied across studies (appendix 2).
Average duration of illness before entry into the study ranged
from less than one to less than four days. Outcomes were
assessed by parents in all studies,22 24-29 clinicians in two
studies,26 28 and children in three studies,25 27 28 with length of
follow-up ranging from two days to a week or, in two studies,22 27
until symptoms resolved. Most studies had a low risk of bias,
except one in which blinding of outcome assessors was
impossible because of the mode of intervention delivery
(intramuscular penicillin v oral placebo)26 (appendix 3).
Measurement of outcomes varied considerably across studies,
involving different methods, assessors, and lengths of follow-up.
Outcomemeasurement was based on standardised scales in only
two studies24 27; the remainder22 25 29 used parental assessment
(by questionnaire, symptom diary, or overall parental
assessment), or clinician assessment.28
Among the four studies that reported mean duration, symptoms
of sore throat lasted from two days to 6.7 days22 24 27 29 (table
3⇓). Though we could not pool data from the three studies that
reported the proportion of children with symptoms because of
insufficient data at several time points, 33-37% of children still
had sore throat symptoms at day three25 26 28 (fig 4⇓, table 3⇓).
Based on visual inspection of the data, time to complete
resolution did not seem to be related to group A β haemolytic
streptococcal infection or duration of symptoms before
enrolment. The single study that reported on duration of fever
reported that 17% of children had fever for less than a day, 11%
had fever one to two days, 44% had fever for two to three days,
and 28% had fever for more than three days.26
Cough (acute cough, bronchiolitis, and croup)
We included six trials of acute cough,30 croup,31-33 or
bronchiolitis,34 35 providing data on 700 children. Five trials took
place in North America30-32 34 35 and one in Australia.33 We
included six observational studies of 1063 children with
cough3 22 36 37 or bronchiolitis,38 39 from the UK,3 36 Poland,22
Australia,37 USA,38 and Canada39 (appendix 2).
Cough was present five to 14 days before study entry among
children with acute cough, four days among children with
bronchiolitis, and one day among children with croup. In most
studies follow-up lasted two to three weeks or until symptoms
resolved (range one to four weeks). Parents assessed outcomes
in all trials and studies that used symptom scales or
scores,30-32 34 39 symptom diaries,3 36-38 standardised
questionnaire,22 or interview.39 Studies had either a low or
moderate risk of bias; those with moderate risk of bias generally
lacked details of randomisation or sequence allocation30 33
(appendix 3).
Among the five studies that reported mean duration of illness,
the time to resolution of cough ranged from one to 25
days3 22 30 36 37 (table 4⇓). Based on the pooled results from five
studies that reported proportions of children with symptoms,
cough had resolved in 50% of children at 10 days, and 90% by
25 days (table 5⇓, fig 5⇓). Symptom duration was relatively
shorter in two studies,22 30 of which one30 was small (n=23) and
enrolled children with symptoms lasting up to 14 days before
recruitment, and the other22 recruited only infants.
The mean duration of croup was two and three days in the two
studies that reported this information32 33 (table 4⇓), and, based
on the pooled data from two studies,31 32 symptoms of croup
resolved in 50% of children at day one and 80% by two days
(table 5, fig 6⇓).
Finally, the mean time to resolution of cough for bronchiolitis
ranged from eight34 to 1538 days (table 4, fig 7⇓). Based on
pooled data from four studies that reported proportions of
children with symptoms,34 35 38 39 50% of children improved by
day 13 (table 5⇓). Though we were unable to determine the time
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for 90% to improve, based on the data presented in figure 7 this
was estimated at 21 days.
Common cold; undefined or non-specific
respiratory tract infections
We included four trials involving 457 children40-43 and 15
observational studies involving 4870 children.7 22 37 44-55 Included
trials and studies were from the US,40 42 43 49 50-52 55 the UK,7 44 53
Finland,41 48 Canada,45 47 Poland,22 Australia,37 Denmark,54 and
Germany46 (appendix 2).
Follow-up ranged from two to 21 days in randomised controlled
trials; in observational studies, follow-up generally lasted two
to three weeks. The mean duration of symptoms before trial
entry ranged from up to one day43 to 8.7 (SD 5.1) days.41
Outcome assessment was performed by parents (using interviews
or symptom diaries) in three trials40 41 43 and by both parents and
children (symptom diary) in one.42Overall, included studies had
low to moderate risk of bias (appendix 3). Treatment and
placebo lozenges were dissimilar in appearance in one
randomised controlled trial, which raised the risk of bias from
inadequate blinding.42 Several studies failed to report
randomisation,40 cohort selection,49 52 or inclusion criteria.7 44 46
Among the four studies that reported mean duration, common
cold symptoms lasted from seven to 15 days22 42 46 51 (fig 8⇓,
table 6⇓). Based on the pooled data from five studies,22 40 42 49 51
by day 10 about 50% of children had improved. We did not
have sufficient data to determine the time at which 90%
improved, but based on visual inspection from figure 8 we
estimated this as about 15 days. The largest study (n=1314)
reported common cold symptoms lasting 1.8 weeks (SD 1.3)
for children aged 7 or younger.46
Themean duration of non-specific respiratory symptoms ranged
from four to 16 days7 43 45 47 48 50 53-55 (table 6⇓). Data on the
proportion of children with symptoms was obtained from 11
studies7 37 41 43-45 47 48 50 53 54 and was highly variable across
individual studies: 50% of children had improved by day seven
to eight and 80% by day 14; we could not identify the time for
90% resolution, although a projected estimate would be around
day 16 (table 7⇓, fig 9⇓). The studies that reported symptoms
at day 14, however, showed an extremely wide range in the
proportion still symptomatic, from 6%44 to 60%.48 The shorter
length of symptom duration reported by both Butler and
colleagues44 and Jacobs and colleagues47 could be explained by
slightly longer average duration of symptoms before study entry.
Taylor and colleagues reported duration of fever of 0.64 mean
days (SD 1.16).43
Discussion
Our review provides parents, clinicians, and policy makers with
up-to-date evidence based estimates of the expected length of
symptoms for children presenting with the most common
respiratory tract infections in primary care and emergency
department settings in high income countries: earache, sore
throat, cough, and non-specific cold symptoms. These infections
were selected because they are common and drive most primary
care consultations and antibiotic prescribing for children in high
income countries. We used data from systematic searches for
both randomised controlled trials (placebo arms) and
observational studies conducted in high income countries. For
many symptoms of respiratory tract infection the data were
highly heterogeneous in terms of age, definition of infection,
outcome assessment, and duration of illness before study entry;
however, our data provide the most robust estimates available.
For some symptoms of respiratory tract infections our estimates
of duration are much longer than those currently used (table
8⇓). For example, for earache (otitis media) we found that 90%
of children are better by seven to eight days, which is
considerably longer than the average duration of four days cited
by the UK National Institute for Health and Care Excellence
and two days cited by the US Centers for Disease Control and
Prevention. In contrast, for some symptoms current estimates
seem to overestimate the expected duration.We found that acute
cough symptoms are better in 50% of children by 10 days, in
contrast with the longer average duration of 21 days cited by
National Institute for Health and Care Excellence. Finally, for
other symptoms, the currently cited estimates of symptom
duration match closely (or are slightly longer) with our
finding—for example, for sore throat/tonsillitis we found that
90% are better by two to seven days, whereas National Institute
for Health and Care Excellence and the Centers for Disease
Control and Prevention cite average durations of seven days
and seven to 14 days, respectively. Similarly, the common cold
seems to last from 10 (50% better) to 15 days (90% better),
similar to advice from both National Institute for Health and
Care Excellence (10-11 days) and the Centers for Disease
Control and Prevention (<14 days).
Strengths and limitations
We believe this is the first systematic review of the duration of
illness for common respiratory tract infections in children. Our
strategy of including data from placebo arms of randomised
controlled trials and from observational studies not only
increases the available data but also provides more generalisable
populations of children. This approach inevitably included
children whomight have been given over-the-counter treatments
for symptoms and, in a few cases, antibiotics. We consider that
it would be unrealistic to restrict our review to children with
respiratory tract infections whowere not given any symptomatic
treatment.While symptomatic treatmentsmight reduce symptom
severity, however, they are unlikely to influence the overall
duration of illness. It is possible that excluding studies of
experimentally induced infection might have reduced eligible
studies, though we do not consider that these types of usually
single pathogen infections reflect the reality of clinical practice,
where patients typically present with clinical syndromes rather
than pathogen specific infections. In synthesising our results,
we opted to present the number of days when 50% and 90% of
children were reported to be asymptomatic. Although the data
were not available for all the respiratory tract infections, we
believe that this additional information avoids the ambiguity of
terms such as “average duration” for parents and clinicians. Our
estimates of duration also apply to children who are given
(usually symptomatic) drugs rather than those given nothing at
all, thereby providing more valuable information for how most
children are managed in the community. As many trials and
studies will have excluded children with severe symptoms, our
findings might not be generalisable to such children or those in
low or middle income countries where risks of complications
are higher. While we included data from both randomised
controlled trials and prospective observational studies, we
excluded retrospective studies, which could be subject to recall
or recording bias.
As with any systematic review, our findings and complexity of
synthesis are limited by the number and quality of included
studies and the data these provided. The included studies were
inevitably clinically heterogeneous in many aspects. The
definition of the respiratory tract infection syndromes differed
(or were poorly defined) in some studies, which could affect
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less discrete conditions (such as the common cold) more than
others (such as croup); though this is a problem with much
research in this area. Secondly, the duration of illness before
study entry varied and was not consistently recorded, which
prevented us from calculating what would have been potentially
more useful for parents—namely, the duration of illness from
initial onset rather than presentation. However, this mirrors the
situation in primary care where patients present in exactly this
way. Thirdly, the lack of sufficient data on age in included
studies meant that we were not able to conduct age specific
analyses. For some infections, however, the age ranges of
children in included studies were relatively narrow (such as for
bronchiolitis and croup) as would be predicted clinically, so
subgroup analysis might not have contributed much to their
interpretation. For other infections, such as sore throat or cough,
the age ranges were much broader and subgroup analysis based
on age would have been useful clinically. Fourthly, the methods
used in individual studies to measure and report symptoms were
highly variable, and the absence of consistent (daily) reporting
for similar durations of follow-up for each respiratory tract
infection meant that we were not able to pool data for all
infections studied. When possible, we attempted to pool results
by calculating mean proportions and 95% confidence intervals,
but this does not take account of the lack of homogeneity
between studies. We attempted to mitigate this by including the
individual study data in all our figures to give some idea of the
variability in symptom projection. Thus, pooled means need to
be interpreted cautiously.
Implications for clinicians, policy, and
research
Our review provides evidence that can be put to daily use by
clinicians and parents caring for children with respiratory tract
infections, as well as informing health policy and evidence based
treatment guidelines. We provide data as far as possible for
number of days for 50% and 90% of children’s symptoms to
have improved; we anticipate that clinicians and parents could
interpret these values into absolute terms as the “time for half
of children” to get better, and “time for 9 out of 10 children” to
get better (table 8⇓). There are two key clinical decisions these
data could inform. First is the parents’ decision to consult
primary care, with its attendant implications for appropriate use
of healthcare resources. Here, the data could inform algorithms
used by healthcare providers (in writing, by telephone, or in
person) to give parents information about expected length of
time that symptoms might last, helping to reassure parents and
trigger consultations more appropriately when the illness seems
to deviate from course. Second is the clinician’s decision to
prescribe antibiotics. Once again, these data could help reassure
clinicians regarding the “normality” of some respiratory
symptoms lasting for longer than previously appreciated and
not necessarily requiring antimicrobial intervention.
We found limited data for the duration of illness for several
respiratory tract infections (such as croup), which suggests that
observational studies would be helpful to increase certainty of
our estimates of duration of symptoms. What parents and
clinicians still need are better ways of predicting which children
will have an adverse or prolonged illness and need additional
treatment (such as antibiotics) or more intensive monitoring
(such as repeated visits). Results of ongoing research efforts
such as the TARGET study (www.targetstudy.org.uk/) will help
to provide these prediction tools. Future research should also
focus the evaluation of new and existing interventions in
children with the most severe illness trajectories.
Conclusions
Parents, clinicians, and policymakers should use these evidence
based estimates of symptom duration when making decision
regarding healthcare seeking and prescribing, and also when
developing clinical guidelines for respiratory tract infections in
children. Widespread dissemination of these data will improve
parental and clinician awareness of how long symptoms last in
children with respiratory tract infections.
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What is already known on this topic
Respiratory tract infections in children are responsible for more primary care consultations that any other group of illnesses
Parents need to know how long symptoms will last to guide help seeking behaviour and use of antibiotics
The scientific basis for current estimates of duration of illness of common respiratory tract infections is not clear and differs between
international bodies such as the UK National Institute for Health and Care Excellence and the US Centers for Disease Control and
Prevention
What this study adds
This systematic review provides new evidence based estimates of the expected duration of the most common respiratory symptoms of
childhood respiratory tract infections, including earache, sore throat, cough, and common cold
There are clinically important differences between the duration estimates we found and those previously published. In most (90%)
children earache was resolved by seven to eight days, sore throat by two to seven days, croup by two days, bronchiolitis by 21 days,
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Tables
Table 1| Duration of earache in children in seven randomised controlled trials and three observation studies
Proportion of children with symptoms
remaining at follow-up:
Mean (SD)
time to
Mean (SD)
symptom
Concurrent
treatment
Mean or range
ageFollow-up
No in
sampleStudy
duration
before study
entry
symptom
resolution
(days) 8 days6 days3 days
Randomised controlled trials
13%18%46%3.3430.1 hoursAB (14%); S3-10 years3 months113Burke, 1991*
—72% (89/123)—9 (median
duration of pain
and crying)
54% had
symptoms
lasting >3 days
S13.3 months6 weeks105Damoiseaux,
2000
47%52%70%—<2 daysS6-23 months21 days139Hoberman,
2011†
——78%
(193/246)
—<4 daysS2.87 years4 months246Le Saux, 2005‡
——38%—≤24 hoursS4.1 years3 months77Mygind, 1981
17%25%56%0.5 (0-5)§<4 daysS5.9 years3 months87Neumark, 2007
04%45%—NRS16 months8 days158Tahtinen, 2011
Observational studies
———6.5 (5.2)NRAB (% NR); S14.8 (SD 8.3)
months
21 days150Greenberg, 2003
———8.6<48 hoursNR<1 yearUntil symptom
resolution
45Jedrychowski,
2005
34% (13/38) with
ear discharge;
20% (44/218)
with no ear
discharge
———NRAB: 92% (ear
discharge),
44% (no ear
discharge)
Median 3 (IQR
1-5) years
3 months256Smith, 2010
AB=antibiotics; NR=not reported; S=symptomatic treatment; IQR=interquartile range.
*Outcome presented is proportion of children with “whose initial episode had persisted up to or beyond that time.”14
†Outcome presented corresponds to the second recording of AOM-SOS of 0 or 1.
‡Outcome presented is proportion of children with ear pain.
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Table 2| Proportion of children with earache on days one to eight in seven randomised controlled trials and three observation studies
Proportion of children (numbers) with symptoms remaining at follow-up
Study Day 8Day 7Day 6Day 5Day 4Day 3Day 2Day 1
Randomised controlled trials
13 (15/118)13 (15/118)18 (21/118)23 (27/118)31 (37/118)46 (54/118)67 (79/118)67 (79/118)Burke, 1991*
————72 (89/123)———Damoiseaux, 2000
—47 (69/147)52 (76/147)55 (81/147)64 (94/147)70 (103/147)86 (126/147)100 (147/147)Hoberman, 2011†
—————22 (53/246)33 (83/250)42 (106/254)Le Saux, 2005‡
—————38——Mygind, 1981
—17 (15/87)25 (22/87)30 (26/87)44 (38/87)56 (49/87)75 (65/87)95 (83/87)Neumark, 2007
0 (0/0)4 (6/160)4 (6/160)17 (27/160)25 (40/160)45 (72/160)63 (101/160)100 (160/160)Tahtinen, 2011
Observational studies
—34 (13/38)§; 20 (44/218)¶——————Smith, 2010
*Outcome presented is proportion of children with “whose initial episode had persisted up to or beyond that time.”14
†Outcome presented corresponds to second recording of AOM-SOS of 0 or 1.
‡Outcome presented is proportion of children with ear pain.
§Children with ear discharge.
¶Children without ear discharge.
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Table 3| Duration of sore throat in children in six randomised controlled trials and one observation study
Proportion of children with sore throat
remaining at follow-upTime to symptom
resolution
Symptom
duration before
study entry
Concurrent
treatmentAge (years)
Follow-up
(days)*
No in
sampleStudy ≥Day 3Day 2Day 1
Randomised controlled trials
———48 hours (95% CI
38.0 to 58.0)
<48 hoursS10.1 (3)†251Bulloch, 2003
33% (57/174)———<48 hoursS2-9357Chapple, 1956
—35% (6/17)53% (9/17)—24 hours
(median)
N5-11317Nelson, 1984
———70.8 (49.6)† hours‡NRS11.3Until
resolution
25Olympia, 2005
37% (12/32)———<1 weekNR8.1 (1.7)†432Ruperto, 2011
———3.5 days (95% CI
2.9 to 4.1)§; 4.7
days (84 to 141.6)‡
3.8 days (mean)S10.1 (3.9)†756Zwart, 2003
Observational study
———6.7 days<48 hours¶NR0-1Until
resolution
103Jedrychowski,
2005
NR=not reported; S=symptomatic.
*Follow-up for outcome of symptom duration.
†Mean (SD)
‡Children without group A streptococcal infection or other culture.
§Children with group A streptococcal infection.
¶To be counted as episode, child must show symptoms for at least one day.
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Table 4| Duration of cough in children in six randomised controlled trials and six observational studies
Proportion of children with cough remaining
at follow-upTime to
symptom
resolution
Symptom
duration
before study
entry
Concurrent
treatmentAgeFollow-up
No in
sampleStudy Weeks 2-4Day 10Day 6Day 3
Acute cough
Randomised controlled trials:
—13%18%58%—1-14 daysAB (38%); S1-10 years7 days23Bernard, 1999
Observational studies:
10% (day
25)
50%75%93%—Median 5 (IQR
3-14) days
AB (18%); SMedian 21 (IQR
8.6-35) months
Until symptom
resolution
228Hay, 2003
25%50% (day
9)
75%——Median 7 daysAB (24%); SMedian 24 (IQR
12-37) months
Until symptom
resolution
154Hay, 2007
————Cough: mean 7.3
days; barking
cough: 5.7 days
<48 hoursNR<1 yearUntil symptom
resolution
225Jedrychowski,
2005
6% (2-4
weeks)
22% (1-2
weeks)
52% (4-7
days)
83%—NRAB (23%); S<5 yearsUntil symptom
resolution
198Kusel, 2007*
Croup
Randomised controlled trials:
———22%—Mean 0.8 (SD
2.4) days
AB (%NR); SMean 35 (SD 23)
months
21 days348Bjornson,
2004†
———58%Median 3 daysMean 1.04 (SD
1.0) days
SMean 21 (SD 8)
months
7-10 days19Cruz, 1995
————Mean 2 (SD 1.6)
days
21 (54) hoursNRMean 45 (SD 26)
months
7-10 days48Geelhoed,
1996
Bronchiolitis
Randomised controlled trials:
—37%73%96%Median 8.4 (3.7)
days; 8.0 days
(95% CI 7 to 9)
Median 4 (IQR
3-7) days
NRMean 5.1 (SD
2.6) months
2 weeks or until
symptom
resolution
61Patel, 2003
————Median 13.3
days (IQR
8.2-19.5)
Median (IQR) 4
(2-6) days
NRMedian 5 (IQR
3-7) months
22 days201Plint, 2009
Observational studies:
25% (day
20)
77%97%100%Median 15 (IQR
11-20)
NRNRMedian 4 (IQR
3-7) months
4 weeks or until
symptom
resolution
95Petruzella,
2010
————Median 12 (IQR
8-20)
Median 4 daysSMedian 5 (IQR
2-8) months
2-3 weeks163Plint, 2004
IQR=interquartile range; NR=not reported; S=symptomatic.
*Outcome is duration of proportion of episodes with cough.
†Outcome is proportion of children with Telephone Outpatient Score of zero.
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Table 5| Proportion of children with cough on days 1-7, 10, 15, and 25 in six randomised controlled trials and six observational studies
Proportion of children with cough remaining at follow-up
Study Day 25Day 15Day 10Day 7Day 6Day 5Day 4Day 3Day 2Day 1
Acute cough
Randomised controlled trials:
———13% (4/29)18% (5/29)27% (8/29)34% (10/29)58% (17/29)83% (24/29)100% (29/29)Bernard, 1999
Observational studies:
10% (22/228)25% (57/228)50%
(114/228)
67% (153/228)75%
(171/228)
80%
(182/228)
85%
(194/228)
93%
(212/228)
96%
(218/228)
98%
(223/228)
Hay, 2003
—25% (41/164)50%
(82/164)
(day 9)
——75%
(123/164)
————Hay, 2007
6% (12/198)
(2-4 weeks)
22% (44/198)
(1-2 weeks)
—52% (103/198)
(4-7 days)
———83%
(164/198) (1-3
days)
——Kusel, 2007*
Croup
Randomised controlled trials:
———————22% (79/361)47%
(170/361)
70%
(253/361)
Bjornson,
2004†
—————————58% (11/19)Cruz, 1995
Bronchiolitis
Randomised controlled trials:
—25% (16/65)37% (24/65)70% (46/65)73% (47/65)86% (56/65)91% (61/65)96% (62/65)100%
(65/65)
100% (65/65)Patel, 2003
25% (at 19.5
days)
50% (at 13.3
days)
—75% (at 8.2
days)
——————Plint 2010
Observational studies:
25% (28/112)50% (56/112)77%
(86/112)
95% (106/112)97%
(109/112)
100%
(112/112)
100%
(112/112)
100%
(112/112)
100%
(112/112)
100%
(112/112)
Petruzella,
2010
25% (at 20
days)
50% (at 12
days)
—75% (at 8
days)
——————Plint, 2004
IQR=interquartile range; NR=not reported; S=symptomatic.
*Outcome is duration of proportion of episodes of cough.
†Outcome is proportion of children with Telephone Outpatient Score of zero.
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Table 6| Duration of common cold and non-specific respiratory illness in children in randomised controlled trials and observational studies
(studies by Grüber, Taylor, and Wald studies not included in line graphs because outcome reported as a range, not mean)
Proportion of children with symptoms
remaining at follow-up:
Mean (SD) time to
symptom resolution
Mean
(SD)
Concurrent
treatmentAgeFollow-upSampleStudy
symptom
duration
before
study
entry Week 2Day 10Day 6Day 3
Common cold
Randomised controlled trials:
———29% (7/24)*—NRS†Mean 25 (SD
15.7) months
48 hours24*Hutton, 1991
30† ——43%
(13/30)†
17%39%80%98%Median 9.0 days (95%
CI 8 to 9)
NRNRMedian 13 (IQR
6-16) years
Until symptom
resolution
122Macknin, 1998
Observational studies:
————1.8 (1.3) weeksNRNR0-7 yearsUntil symptom
resolution
1314Grüber,
2007‡
1.5 (1.6) to 1.8 (2.4)
weeks
Infants
2.1 (3.2) weeks3 years
1.3 (1.4) weeks7 years
————7.6 days< 48 hoursNR<1 yearUntil symptom
resolution
292Jedrychowski,
2005
—74%90%100—NRSNR10 days81Pappas,
2008§
————Clear rhinorrhoea: 13.5
(3.5) days
NRNR25 monthsUntil symptom
resolution
40Steinweg,
1983
Purulent rhinorrhoea:
14.8 (4.2) days
Respiratory tract infection
Randomised controlled trials:
43%
(16/37)
————8.7 (5.1)
days
NRMean 6.9 (SD
2.0) years
2 weeks37Kristo, 2005
————Median 9 days (95% CI
8 to 10)
≤24 hoursAB (7.3%)Mean 5.4 (SD)
2.5 years
Until symptom
resolution (≤21
days)
244Taylor, 2003
Observational studies:
6%
(10/169)
9%
(15/171)
32%
(57/179)
71%
(131/184)
—3.3 (2.18)
days
Intranasal
sodium
cromoglicate
or saline
(100%)
Mean 5.1 (SD
3.4) years
2 weeks169Butler,
2002/03
—50%——10.22 days (95% CI
9.14 to 11.29);
median 7.86 days
NRNRMean 24.55 (SD
6.12) months
10 days333Carabin, 2000
5%10%50%75%Median 4.5 days<72 hoursAB (24%)Median 3.2
years
2 weeks206Jacobs, 2000
60%81%98%100Middle meatal
pathogen: present: 16.7
(7.0) days;
4 daysAB (6%); SMedian 9.8
(IQR 6-13)
years
3 weeks38Kristo, 2006
43%67%90%100Middle meatal pathogen
absent: 13.1 (6.0) days
42
23% (1-2
wks)
—59% (4-7
days)
91% (1-3
days)
—NRAB (21%); S<5 yearsUntil symptom
resolution
236Kusel, 2007¶
25%50%75%—Median 7 days (IQR
5-11)
NRNRMean 8 yearsUntil symptom
resolution (≤21
days)
223Mitra, 2011
——50%—Median 6 days≥ 2 daysNRInfant30 days1209Samet, 1993
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Table 6 (continued)
Proportion of children with symptoms
remaining at follow-up:
Mean (SD) time to
symptom resolution
Mean
(SD)
symptom
duration
before
study
entry
Concurrent
treatmentAgeFollow-upSampleStudy Week 2Day 10Day 6Day 3
——48.3%Sneezing:
66.1%
—NRNRMean 6 (SD
2.7) years
4 days148Taylor,
2010**
——50.9%Runny nose:
41%
——39%Cough:
37.7%
——44.1%Nasal
congestion:
59%
———8.28 (4) days≥ 24 hoursNRMean 9.31 (SD
2.4) years
15 weeks116Turner Cobb,
1998
————Median 4.7 days; (IQR
2-6) days
NRAB (38%); S<1 yearUntil symptom
resolution
217von Linstow,
2008
————HC: 7.33 (5.54) days;
GC: 8.32 (6.19) days;
DC: 8.87 (6.72) days
≥ 24 hoursNR<1 yearUntil symptom
resolution
244Wald, 1991
HC: 6.63 (5.13) days;
GC: 7.98 (6.67) days;
DC: 7.29 (6.54) days
1-2 years
HC: 6.79 (4.96) days;
GC: 7.20 (5.84) days;
DC: 7.82 (6.40) days
2-3 years
AB=antibiotics, HC=home care; GC=group care; DC=day care; NR=not reported; S=symptomatic.
*Placebo.
†No treatment.
‡Outcomes are means (standard deviation).
§Outcome is “proportion of children reporting any symptom by day of illness in 81 common colds.”
¶Outcome is duration of proportion of episodes.
**Outcomes are for children with viral RTI.
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Table 7| Proportion of children with common cold and non-specific respiratory illness on days 1-14
Proportion of children with symptoms remaining at follow-up:
Study 1413121110987654321
Common cold
Randomised controlled trials
————————————71%
(17/24)*;
57%
(17/30)†
—Hutton,
1991
17%
(21/124)
23%
(29/124)
25%
(31/124)
28%
(34/124)
39%
(48/124)
51%
(63/124)
60%
(74/124)
68%
(84/124)
80%
(99/124)
88%
(109/124)
98%
(122/124)
98%
(122/124)
100%
(124/124)
100%
(124/124)
Macknin,
1998
Observational studies
————74%
(60/81)
80%
(64/81)
82%
(66/81)
88%
(71/81)
90%
(73/81)
97%
(79/81)
97%
(79/81)
100%
(81/81)
100%
(81/81)
100%
(81/81)
Pappas,
2008‡
Respiratory tract infection
Randomised controlled trials
43%
(16/37)
—————————————Kristo,
2005
Observational studies
6% (10/
169)
6%
(10/169)
7%
(12/169)
8%
(14/169)
9%
(15/171)
11%
(19/175)
16%
(28/175)
26%
(49/189)
32%
(57/179)
39%
(71/181)
56%
(101/181)
71%
(131/184)
91%
(171/188)
96%
(185/193)
Butler,
2002/03
——————50%
(167/333)
———————Carabin,
2000
5%
(11/220)
———10%
(22/220)
——25%
(55/220)
—50%
(110/220)
—75%
(165/220)
——Jacobs,
2000
Kristo, 2006:
60%
(23/38)
63%
(24/38)
69%
(26/38)
79%
(30/38)
81%
(31/38)
90%
(34/38)
95%
(36/38)
97%
(37/38)
98%
(37/38)
100%
(38/38)
100%
(38/38)
100%
(38/38)
100%
(38/38)
100%
(38/38)
Middle
meatal
pathogen
43%
(18/42)
52%
(22/42)
61%
(25/42)
63%
(26/42)
67%
(28/42)
79%
(33/42)
81%
(34/42)
86%
(36/42)
90%
(38/42)
99%
(41/42)
100%
(42/42)
100%
(42/42)
100%
(42/42)
100%
(42/42)
Nomiddle
meatal
pathogen
23%
(1-2
wks)
(46/198)
——————59% (4-7
days)
(117/198)
———91% (1-3
days)
(180/198)
——Kusel,
2007§
———25%
(143/570)
———50%
(285/570)
—75%
(428/570)
————Mitra, 2011
————————50%
(658/1315)
—————Samet,
1993
————25%
(65/261)
50%
(131/261)
75%
(196/261)
———————Taylor,
2003
Taylor, 2010:
——————————48.3%
(72/150)
——: 66.1%
(99/150)
Sneezing
——————————50.9%
(76/150)
41%
(62/150)
47.5%
(71/150)
: 38.7%
(58/150)
Runny
nose
——————————39%
(59/150)
37.7%
(57/150)
41%
(62/150)
30.7%
(46/150)
Cough:
——————————44.1%
(66/150)
59%
(89/150)
——Nasal
congestion
*Placebo.
†No treatment
‡Outcome presented is “proportion of children reporting any symptom by day of illness in 81 common colds.”
§Outcome presented is duration of proportion of episodes.
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Table 8| Duration of common respiratory tract infections in children in current systematic review compared with current advice from UK
National Institute for Health and Care Excellence (NICE) and the US Centers for Disease Control and Prevention (CDC)
Average illness duration(days)
Time (days, unless otherwise stated) for symptoms to
resolve
CDCNICE8In 90% of childrenIn 50% of children
——2*1Croup
2-3†47-83Earache/otitis media
7-14§72-7‡—Sore throat/tonsillitis
——16¶7Non-specific respiratory tract
infection
14††10-1115**10Common cold
10-14‡‡212510Acute cough
——21§§13Bronchiolitis
*No of days to 80% resolution.
†Data from www.cdc.gov/getsmart/campaign-materials/info-sheets/child-otitismedia.pdf
‡Data not sufficient to calculate pooled proportions or time to 50% or 90% resolution; figures shown are ranges from included studies for days to complete resolution.
§Data from www.cdc.gov/getsmart/antibiotic-use/URI/sore-throat.html
¶Data from pooled proportions did not extend beyond time to 80% resolution (14 days), data presented is estimate for time to 90% resolution from fig 9.
**Data from pooled proportions did not extend beyond time to 60% resolution (10 days), figure shown is estimate for time to 90% resolution from fig 8.
††Data from www.cdc.gov/getsmart/campaign-materials/info-sheets/child-rhin-vs-sinus.pdf
‡‡Data from www.cdc.gov/getsmart/campaign-materials/info-sheets/child-cough-illness.pdf
§§No of days estimated from fig 7. Time to 60% resolution was 16 days.
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Figures
Fig 1 Flow of included randomised controlled trials of respiratory tract infections in children
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Fig 2 Flow of included observational studies of respiratory tract infections in children
Fig 3 Proportion of children with symptoms of earache. Symptom duration before study onset was less than four days in
five studies (Burke,14Damoiseaux,15 Le Saux,17Neumark,19 Jedrychowski22) and was not reported in three studies (Tahtinen,20
Greenberg,21 Smith23)
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Fig 4 Proportion of children with symptoms of sore throat. Symptom duration before study onset ranged between 24 hours
(median) (Nelson26) to less than one week (Ruperto28) and was not reported in one study (Olympia27). *Children with group
A streptococcal infection; †children without group A streptococcal infection or other culture. (Pooling not possible because
of lack of data)
Fig 5 Proportion of children with symptoms of cough. Symptom duration before study onset ranged between <48 hours
(Jedrychowski22) to <14 days (Bernard30) and was not reported in one study (Kusel37)
Fig 6 Proportion of children with symptoms of croup. Mean symptom duration before study onset was reported as 0.8 (2.4)
days (Bjornson31), 1.04 (1) days (Cruz32), and 21 (54) hours (Geelhoed33)
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Fig 7 Proportion of children with symptoms of bronchiolitis. Symptom duration before study was median four days in three
studies (Patel,34 Plint 2009,35 Plint 200439) and not reported in one study (Petruzella38)
Fig 8 Proportion of children with symptoms of common cold. Symptom duration before study onset was not reported in five
studies (Hutton, Macknin, Gruber, Pappas, Steinweg), Jedrychowski et al reported duration <48 hours.22 *Placebo arm;
†no treatment arm; ‡children with clear rhinorrhoea; §children with purulent rhinorrhoea
Fig 9 Proportion of children with non-specific respiratory symptoms. Symptom duration before study onset ranged between
≤24 hours (Taylor 200343) to 8.7 (5.1) mean days (Kristo41) and was not reported in five studies (Carabin,45 Kusel,37 Mitra,7
Taylor 2010,52 Von Linstow54). *Middle meatal pathogen present; †middle meatal pathogen absent
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